arXiv:2608. 05359v1 Announce Type: new Abstract: CASCADE is an agentic framework that predicts downstream transcriptional effects of gene perturbation from precomputed ARACNe regulatory networks, exposed via MCP.
By Jose A. Bird
arXiv:2408. 13378v5 Announce Type: replace Abstract: Workflows in drug-target interaction (DTI) assessment require integrating heterogeneous data from predictive models, curated resources, and observations from experimental literature.
By Yoshitaka Inoue, Tianci Song, Xinling Wang, Rui Kuang, Tianfan Fu, Augustin Luna
arXiv:2608. 07609v1 Announce Type: cross Abstract: High-throughput screening (HTS) assays are central to early-stage drug discovery but are often limited by extreme data sparsity, as primary screens typically use only a single replicate per test substance.
By Xiaohua Douglas Zhang
arXiv:2606. 11144v1 Announce Type: new Abstract: Resistance to first-line osimertinib in EGFR-mutant non-small-cell lung cancer (NSCLC) is the canonical example of predictable clonal evolution under therapeutic pressure, yet no public benchmark exists for training or evaluating computational models on the corresponding longitudinal patient trajectories.
By Abhijoy Sarkar, Aarchi Singh Thakur
The study evaluates whether a portfolio of compact, semantically named descriptor blocks can match the performance of a 2048‑dimensional CheMeleon embedding in low‑data molecular assays. Using a fixed 11‑dimensional physicochemical base and greedily adding provenance‑screened blocks, the portfolio achieves a mean test AUC of 0.762 across nine ADME/Tox assays, comparable to CheMeleon’s 0.764 and better than Mordred’s 0.756. The results meet a predeclared pooled parity threshold but not all per‑assay thresholds, and further analysis confirms the competitiveness of the auditable representation while highlighting unresolved assay‑level differences.
By Yiqi Yao, Miquel Duran-Frigola
FedHisto-PAST v2 is a parameter‑efficient, stain‑aware federated learning framework for cross‑site lung histopathology classification, combining a frozen HIBOU‑B foundation model with techniques such as paired‑view prediction, feature consistency, prototype learning, and adaptive aggregation. In a five‑client, non‑IID simulation and an exploratory LungHist700 cohort, the method achieved a Macro‑F1 of 0.7286 and a balanced accuracy of 0.7305, with the prediction‑level consistency component providing the most clear independent benefit. The framework updated only about 1.25% of the model parameters, demonstrating efficient adaptation while acknowledging limitations in privacy guarantees and clinical validation.
By Muhammad Muhtasim Shahriar, M. M. Golam Hafiz, Saad Aloteibi, Mohammad Ali Moni